Theradaptive250Frederick-based biopharmaceutical company Theradaptive Thursday announced it has closed a $26 million Series A funding round to advance development of its targeted regenerative therapeutics.

The funds are intended to enable the company to continue its work to meet regulatory requirements and scale up Good Manufacturing Practices in preparation for first-in-human clinical trials later this year. Investment will also support the expansion of the Theradaptive platform beyond orthopedics to additional indications such as oncology and dental. The round brings Theradaptive’s total funding to more than $50 million.

The company has previously been awarded non-dilutive grant funding from the Department of Defense, as well as the Maryland Stem Cell Research Fund.

Click here to read more via The Daily Record.